AstraZeneca to buy 55% of biotech firm Acerta for $4b, to get cancer drug

AstraZeneca to buy 55% of biotech firm Acerta for $4b, to get cancer drug

A sign is seen at an AstraZeneca site in Macclesfield, central England in this May 19, 2014 file photo. REUTERS/Phil Noble

Ben Hirschler

17 December, 2015

AbbVieacalabrutinibacerta pharmaAstraZenecaCrestorDeutsche BankGoldman SachsImbruvicaJefferiesJohnson & JohnsonNexiumzs pharma

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter

Read more from World

Nikkei Logo
DealStreetAsia Logo
About Us
Team
Advertise
Contact
Careers
Blog
Privacy Policy
Terms & Conditions
© Copyright DEALSTREETASIA 2014-2025 All rights reserved.